Compare Bristol-Myers Squibb Co (BMY) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.85. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | JNK | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Fixed Income |
52-Week High | $65.89 | $98.19 |
52-Week Low | $42.60 | $94.66 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
JNK trades at $95.85, up 0.21% with a bearish technical signal from moving averages and oscillators neutral. Recent news highlights bond market volatility amid inflation data and Middle East tensions, with Fitch Ratings warning of AI-related corporate credit risks. The ETF maintains dividend distributions, with recent payouts around $0.52-$0.53.
Outlook is cautious due to macroeconomic headwinds and credit risks, but higher yields may attract income investors. Key risks include Fed policy uncertainty and oil price fluctuations impacting bond markets. Analyst sentiment is mixed, balancing yield appeal against fee concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
